Actively Recruiting
Studying Immune Response to Neoadjuvant Immunochemotherapy in Women with Early Triple-Negative Breast Cancer
Led by Center Eugene Marquis · Updated on 2026-07-10
200
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating the cellular and molecular factors that influence how women aged 18 and older with early-stage triple-negative breast cancer TNBC respond to neoadjuvant immunochemotherapy. The study aims to understand if detailed immune profiling of the tumor and its surrounding environment can predict whether patients achieve a complete pathological response or have a partial or no response. It also explores specific immune and molecular biomarkers that might be linked to progression-free and overall survival in this group. Participants will undergo an initial tumor biopsy before starting treatment, along with the placement of an intra-tumoral clip. They will also provide annual blood samples for up to five years to monitor tumor biomarkers circulating in the blood. This observational study follows patients receiving immunochemotherapy according to the Keynote-522 regimen and tracks clinical events and biomarker changes over time. During the study, women will be assessed through pre-treatment tumor biopsies and yearly blood draws for five years. Researchers will monitor immune markers and clinical outcomes to compare those who respond fully to treatment with those who do not. The primary outcomes focus on immune factors related to treatment response, progression-free survival, and overall survival over the five-year follow-up period. Participants will be followed closely to gather this information to help guide personalized treatment strategies.
CONDITIONS
Brief Title
Predicting Response to Immunochemotherapy in Early Triple Negative Breast Cancer
Research Team
V
Valérie JOLAINE
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here